Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fedratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 10/20 | 0.97 |
| ▸ | FLT3 known ✓ | P36888 | 4/20 | 0.97 |
| ▸ | BRD4 | O60885 | 13/20 | 0.97 |
| ▸ | JAK1 | P23458 | 10/20 | 0.97 |
| ▸ | JAK3 | P52333 | 7/20 | 0.97 |
| ▸ | TYK2 | P29597 | 4/20 | 0.97 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.97 |
| ▸ | RET | P07949 | 3/20 | 0.97 |
| ▸ | WEE1 | P30291 | 2/20 | 0.97 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.97 |
| ▸ | AXL | P30530 | 2/20 | 0.97 |
| ▸ | MERTK | Q12866 | 2/20 | 0.97 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.97 |
| ▸ | PLK4 | O00444 | 1/20 | 0.97 |
| ▸ | STK25 | O00506 | 1/20 | 0.97 |
| ▸ | CIT | O14578 | 1/20 | 0.97 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.97 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.97 |
| ▸ | IKBKB | O14920 | 1/20 | 0.97 |
| ▸ | CASK | O14936 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fedratinib SCHEMBL2732092 | 1.00 | BRD4 (0.97) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL2734027 | 0.99 | BRD4 (0.98) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL29351417 | 0.98 | BRD4 (1.00) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL263741 | 0.98 | BRD4 (1.00) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL21773088 | 0.94 | BRD4 (0.91) | BRD4JAK2JAK1JAK3TYK2 | |
| Fedratinib SCHEMBL21773035 | 0.94 | BRD4 (0.91) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL21784856 | 0.92 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL29188523 | 0.92 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL31077598 | 0.92 | BRD4 (0.87) | BRD4JAK2JAK1JAK3TYK2 | |
| SCHEMBL31163072 | 0.92 | JAK1 (0.86) | BRD4JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4663240-A1 | IFN- PATHWAY INHIBITORS FOR USE IN THE TREATMENT OF FSHD | Ospedale San Raffaele S.r.l. (IT) | 2025-12-17 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-20250101427-A1 | COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES | UNIV CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | BROWN UNIVERSITY | 2024-10-31 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| CN-116829142-A | Methods for treating and ameliorating cancer | 加利福尼亚大学董事会 | 2023-09-29 | — | — | CN | claimed |
| WO-2023164455-A2 | COMPOSITIONS AND METHODS TO MODULATE THE IMMUNE SYSTEM | ALOE THERAPEUTICS INC (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230173295-A1 | Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| EP-4159216-A1 | COMPOSITIONS FOR TREATING MYELOFIBROSIS | Impact Biomedicines, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2023004113-A2 | COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-26 | — | — | WO | claimed |
| EP-4110351-A1 | LIQUID BIOPSY YIELD ENHANCEMENT | Singhal, Seema (US) | 2023-01-04 | — | — | EP | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022159624-A1 | LIQUID BIOPSY YIELD ENHANCEMENT | SINGHAL SEEMA (US) | 2022-07-28 | — | — | WO | claimed |
| US-11324750-B2 | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | SLC19A1, SLC5A7, FABP7 | JAK2 2234/4885FLT3 1274/4885BRD4 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.